The DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
Promising candidates from drug clinical trials: Implications for clinical treatment of Alzheimer's disease in China
Open accessAbstract
Alzheimer's disease is the most common neurodegenerative disease. Prior to 2017, National Medical Products Administration approved only four drugs to treat Alzheimer's disease, including three cholinesterase inhibitors and one N-methyl-D-aspartate receptor antagonist. We queried ClinicalTrials.gov to better understand Alzheimer's drug development over the past 5 years and found 16 promising candidates that have entered late-stage trials and analyzed their impact on clinical treatment of Alzheimer's disease in China. The 16 compounds selected include disease-modifying therapies and symptomatic therapies. The research and development pipeline now focuses on disease-modifying therapies such as gantenerumab, aducanumab, ALZ-801, ALZT-OP1, donanemab, lecanemab, simufilam, NE3107, semaglutide, and GV-971, which could put an end to the situation where Alzheimer's patients in China have no effective treatment alternatives. The reuse of drugs or combinations currently under investigation for the psychiatric treatment of Alzheimer's disease, including AXS-05, AVP-786, nabilone, brexpiprazole, methylphenidate, and pimavanserin, could provide physicians with additional treatment options. Although most of these drugs have not been explored in China yet, due to the current development trend in this field in China, it is expected that China will be involved in research on these drugs in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In interim results from its phase II trial (NCT04693520), the drug lowered biomarker levels and showed the potential to slow the decline in memory and learning abilities in early AD patients carrying the APOE4 gene (either APOE4/4 or APOE3/4).425”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [425]
The cited source says what the claim attributes to it.
In the citing paper
“Brexpiprazole (11), commonly prescribed for depression and schizophrenia, targets serotonin, dopamine, and norepinephrine receptors. It is known to help mitigate agitation in individuals with AD.425–427”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [425]
The cited source says what the claim attributes to it.
In the citing paper
“NE3107 (25, formerly HE3286) is a small insulin sensitizer that inhibits inflammation.425”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [425]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
2020 Alzheimer's disease facts and figures
(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728 · cited 3×
“Despite mixed secondary outcomes, donanemab has a better composite score for cognition and ability to perform activities of daily living than placebo (35).”
BackgroundInfluentialWang, X., Sun, G., Feng, T., Zhang, J., Huang, X., Wang, T., Xie, Z., Chu, X., Yang, J., Wang, H., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0216-x · Cited by 1,144
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Burns, A., & Iliffe, S. (2009) · BMJ · doi:10.1136/bmj.b158 · Cited by 859
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Swanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00813-8 · Cited by 847 · cited 3×
“However, the 12-month primary endpoint was not met (31).”
BackgroundMethodInfluentialKellar, D., & Craft, S. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30231-3 · Cited by 832
Research works printed but not linked: 16
- 2019, Caring for the Elderly, Please Pay Attention to Alzheimer's Disease.
- Jinzhou, 2021, Chinese guidelines for the diagnosis and treatment of Alzheimer's Disease (Version 2020), Chin J Gerontol., 40, 269, 10.3760/cma.j.issn.0254-9026.2021.03.001 · doi:10.3760/cma.j.issn.0254-9026.2021.03.001
- America, 2016, Researching Alzheimer's Medicines: Setbacks and Stepping Stones, 2012.
- 2021, Aduhelm
- Cavazzoni, 2021, Fda's Decision to Approve New Treatment for Alzheimer's Disease.
- Dutton, 2021, New Drug Approval Could Be on Horizon for Alzheimer's after 17-Year Drought
- 2021, Lecanemab (Also Called Ban2401)
- 2021, Lecanemab Sweeps up Toxic Aβ Protofibrils, Catches Eyes of Trialists
- MS, 2022, Simufilam (Pti-125).
- 2020, Sodium Oligomannate Capsules: Chinese Prescribing Information.
- 2018, Fits and Starts: Trial Results from the Ctad Conference
- Jacobson, 2020, Advance-1 Phase 2/3 Trial of Axs-05 in Alzheimer's Disease Agitation Topline Results.
- 2011, FDA Drug Approval Package: Nuedexta (Dextromethorphan Hydrobromide and Quinidine Sulfate) Capsules.
- Inc, 2015, Avanir Pharmaceuticals Announces Initiation of Phase Iii Trial of Avp-786 for Agitation in Patients with Alzheimer's Disease
- 2015, Avanir Pharmaceuticals Announces Initiation of Phase Iii Trial of Avp-786 for Agitation in Patients With Alzheimer's Disease
- Verghese, 2021, Methylphenidate.
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Alzheimer’s Disease: The Past, Present, and Future of a Globally Progressive Disease
Vejandla, B., Savani, S., Appalaneni, R., Veeravalli, R. S., & Gude, S. S. (2024) · Cureus · doi:10.7759/cureus.51705 · Cited by 54
Liu, W., Li, Y., Zhao, T., Gong, M., Wang, X., Zhang, Y., Xu, L., Li, W., Li, Y., & Jia, J. (2023) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2023.102534 · Cited by 46
The Application of Deuteration Strategy in Drug Design
Chen, Y., & Du, Y. (2024) · ChemMedChem · doi:10.1002/cmdc.202400836 · Cited by 39
The Vascular-Immune Hypothesis of Alzheimer’s Disease
Mehta, R. I., & Mehta, R. I. (2023) · Biomedicines · doi:10.3390/biomedicines11020408 · Cited by 40
Metadata
- Authors
- Cao, Y., Yu, F., Lyu, Y., & Lu, X.
- Affiliations
- China Pharmaceutical University (CN)
- Fudan University (CN)
- Anhui Medical University (CN)
- Corresponding author
- Lyu, Yi
- Lu, Xianfu
- ORCID
- Lu, Xianfu
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2022-11-15
- Volume
- 13
- Pages
- 1034243-1034243
- ISSN
- 1664-2295 (ISSN-L)
- PMC
- PMC9706102
- OpenAlex
- W4309212128
- Cited by
- 26
- References
- 69
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 9 · 2023: 4
- FWCI
- 0.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Neurology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, drug development pipeline, late-stage clinical trials, disease-modifying therapy, symptomatic treatment, gantenerumab, aducanumab, donanemab, lecanemab, semaglutide, drug repurposing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Promising candidates from drug clinical trials: Implications for clinical treatment of Alzheimer's disease in China. https://app.cochat.ai/papers/10.3389/fneur.2022.1034243
- The paper
- Cao, Y., Yu, F., Lyu, Y., & Lu, X. (2022). Promising candidates from drug clinical trials: Implications for clinical treatment of Alzheimer's disease in China. Frontiers in Neurology. https://doi.org/10.3389/fneur.2022.1034243
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.